IGM Biosciences Inc

NASDAQ:IGMS   4:00:00 PM EDT
15.00
+1.11 (+7.99%)
: $14.62 -0.38 (-2.53%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)960.87M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.23 Million
Adjusted EPS-$0.80
See more estimates
10-Day MA$14.71
50-Day MA$12.31
200-Day MA$10.55
See more pivots

IGM Biosciences Inc Stock, NASDAQ:IGMS

325 East Middlefield Road, Mountain View, California 94043
United States of America
Phone: +1.650.965.7873
Number of Employees: 224

Description

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm�s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.